GRAIL, Inc.: insider trades · United States · SEC (Form 4)

About GRAIL, Inc.

GRAIL, Inc. (ticker: GRAL) is a U.S.-based healthcare company listed on the NASDAQ in the United States. It operates at the intersection of diagnostics, oncology, and preventative medicine, with a core mission to detect cancer early, when it can be cured. Its flagship commercial product is Galleri®, a multi-cancer early detection (MCED) blood test designed to identify cancer signals before symptoms appear. GRAIL’s technology platform also extends beyond a single product: the company uses next-generation sequencing, methylation-based analysis, machine learning, software, and automation to build a broader precision-oncology and early-detection franchise. The company traces its roots to the scientific and commercial ecosystem around Illumina, and it became an independent public company after the spin-off of GRAIL from its former parent. GRAIL is headquartered in Menlo Park, California. From an investor’s standpoint, the company’s story is centered on a large unmet clinical need: broad-based cancer screening that can improve outcomes by shifting diagnosis earlier in the disease course. That makes GRAIL a high-potential but also highly execution-dependent healthcare name. In competitive terms, GRAIL holds a distinctive position in an emerging category. Galleri is one of the best-known commercial MCED tests in the market, and its differentiation lies in its ability to screen for many of the deadliest cancers from a single blood draw. When a signal is detected, Galleri provides a cancer signal of origin to help guide downstream diagnostic work-up. This creates a potentially compelling value proposition for patients, providers, and health systems, although adoption still depends on clinical confidence, reimbursement, regulatory progress, and integration into care pathways. GRAIL’s commercial footprint is primarily in the United States, while its scientific and regulatory profile is supported by international clinical programs, including the NHS-Galleri trial in England. Recent developments have been notable. On February 19, 2026, the company reported full-year 2025 results and said it sold more than 185,000 Galleri tests in 2025, with U.S. Galleri revenue up 26% year over year. GRAIL also completed its FDA PMA submission in January 2026, announced topline results from the NHS-Galleri trial, and completed analysis of the full PATHFINDER 2 study. In April 2026, it announced integration of Galleri into the Epic electronic health record platform, a potentially meaningful step toward broader health-system adoption. Overall, GRAIL remains a commercialization-and-evidence-building story with significant strategic optionality in a large addressable market.